SCHEMBL25028691

SCHEMBL25028691

Cc1nc(-c2c[nH]c3c(C#N)cccc23)cnc1NCC(O)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.44
▸ GSK3B P49841 2/20 0.44
▸ NFATC1 O95644 1/20 0.44
▸ CCNT1 O60563 1/20 0.38
▸ CCNK O75909 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ CDK12 Q9NYV4 1/20 0.38
▸ NR3C1 P04150 1/20 0.38
▸ PGR P06401 1/20 0.38
▸ NR3C2 P08235 1/20 0.38
▸ IRAK1 P51617 2/20 0.35
▸ AR P10275 7/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ LRRK2 Q5S007 2/20 0.32
▸ SLC6A4 P31645 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ SLC22A1 O15245 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29364627 1.00 DYRK1A (0.44) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL26180188 0.89 DYRK1A (0.49) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL29365109 0.83 GSK3B (0.47) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL25029340 0.83 GSK3B (0.47) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL29005446 0.80 GSK3B (0.45) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL29364153 0.77 GSK3B (0.46) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL25029067 0.77 GSK3B (0.46) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL25029095 0.76 DYRK1A (0.56) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL29364759 0.76 DYRK1A (0.56) DYRK1AGSK3BNFATC1CCNT1CCNK
SCHEMBL25259473 0.75 GSK3B (0.46) DYRK1AGSK3BNFATC1CCNT1CCNK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348439-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2023-11-02 — — US disclosed
US-11667624-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2023-06-06 — — US disclosed
US-11667624-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2023-06-06 — — US disclosed
US-20230049406-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049406-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 DYRK1A 1187/4885GSK3B 463/4885NFATC1 1397/4885
US-20230348439-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 DYRK1A 1097/4885GSK3B 441/4885NFATC1 1359/4885
US-11667624-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 DYRK1A 937/4885GSK3B 468/4885NFATC1 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback